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HAVEL,PETER J., DAVID E. FLATNESS,JEFFREYB.HALTER, 
JAMES D.BEsT, RICHARD C.VEITH, AND GERALD J. TABOR- 
SKY, JR. Halothane anesthesia does not suppress sympathetic 
activation produced by neuroglucopenia. Am. J. Physiol. 252 
(Endocrinol. Metab. 15): E667-E672,1987.-To determine the 
suitability of halothane anesthesia for studies of sympathetic 
control of the endocrine pancreas in dogs, we assessed the effect 
of halothane anesthesia (0.8% inspired concentration) on the 
sympathetic response to central neuroglucopenia. In dogs anes- 
thetized with halothane, intravenous administration of the 
neuroglucopenic agent, 2-deoxy-D-glucose (2-DG; 100 mg/kg), 
produced increases of both systemic plasma epinephrine (EPI; 
A = 269 ~fr 86 pg/ml, P < 0.025) and norepinephrine (NE; A = 
157 t 55 pg/ml, P < 0.025) equivalent to those previously 
observed in conscious dogs. Measurement of plasma NE kinet- 
ics revealed that the plasma NE response to 2-DG during 
halothane was due to an increase in the rate of NE appearance 
that was identical to that of conscious dogs, rather than to an 
impairment of NE clearance. In contrast, 2-DG at this dose did 
not increase plasma EPI or NE levels in dogs anesthetized with 
pentobarbital sodium (30 mg/kg). Plasma glucose increased 
modestly after 2-DG (100 mg/kg) in both conscious and halo- 
thane-anesthetized dogs but not in the pentobarbital-anesthe- 
tized dogs. Although 2-DG at a threefold higher dose (300 mg/ 
kg) caused plasma EPI, NE, and glucose (A = 12 t 3 mg/dl; 
P c 0.001) to increase in pentobarbital-anesthetized dogs, the 
responses to this higher dose of 2-DG were all significantly 
larger in halothane-anesthetized dogs (A of plasma glucose = 
30 + 8 mg/dl, P c 0.005; P c 0.0025 vs. pentobarbital). The - 
catecholamine data demonstrate that halothane is a more suit- 
able anesthetic than pentobarbital for use in experiments 
studying reflex neuroglucopenic activation of the sympathetic 
nervous system. The glucose data suggest that certain metabolic 
responses secondary to sympathetic activation are also pre- 
served in halothane-anesthetized animals. 
21). Such suppression could abolish or obscure the po- 
tential contribution of the sympathetic nervous system 
to the pancreatic endocrine and metabolic responses to 
autonomic activation that would normally occur in the 
conscious animal. 
The demonstration that halothane is less suppressive 
than pentobarbital on certain cardiovascular reflexes (6) 
and on a pancreatic parasympathetic reflex, the pan- 
creatic polypeptide response to neuroglucopenia (11)) led 
us to evaluate the effect of halothane on the sympathetic 
responses to neuroglucopenia. 
To test whether halothane anesthesia is less suppres- 
sive than pentobarbital on the sympathetic and meta- 
bolic response to neuroglucopenia, we measured the 
changes of systemic plasma EPI, NE, and glucose levels 
after the administration of the neuroglucopenic agent, 2- 
DG, in dogs anesthetized with 0.8% inspired halothane. 
These responses were then compared with those re- 
sponses previously measured in both conscious and pen- 
tobarbital-anesthetized dogs (23). To verify that the 
plasma NE response to 2-DG in halothane-anesthetized 
dogs was due solely to increased NE release, rather than 
to a reduction of plasma NE clearance, we measured 
plasma NE kinetics before and during neuroglucopenia 
in halothane-anesthetized and conscious dogs. 
MATERIALS AND METHODS 
Animals and surgical procedures. Sixteen dogs of mixed 
breed weighing from 29 to 42 kg were used in the exper- 
epinephrine; norepinephrine; norepinephrine kinetics; pento- 
barbital sodium, plasma glucose; 2-deoxy-D-glucose; dog 
iments with halothane anesthesia. Eight other conscious 
dogs were used in the NE ki netic experiments. C atheters 
were chronically imp1 .anted in the thoracic aorta of these 
dogs (11). All animals were fasted overnight (18 h) before 
the experiments were started. 
WE HAVE RECENTLY DEMONSTRATED thatpentobarbital 
sodium suppresses the plasma epinephrine (EPI), nor- 
epinephrine (NE), and glucose responses to the neuro- 
glucopenic agent, Z-deoxy-D-glucose (2DG) (23). Pen- 
tobarbital also suppresses other central reflexes (7, 24, 
25) and in addition inhibits axonal conduction (14) and 
transmission across peripheral autonomic ganglia (10, 
Protocols. To determine the effects of halothane an- 
esthesia on reflex activation of the sympathetic nervous 
system produced by Z-DG, dogs bearing previously im- 
planted catheters were anesthetized with halothane. An 
ultrashort-acting barbiturate, thiamylal sodium (18 mg/ 
kg, Surital, Parke, Davis), was used for induction. Then 
an endotracheal tube was inserted and the animal was 
ventilated with an ai .r-driver respirator connected to a 
vaporizer (Draeger, FRG) supplying halothane (0.8% 
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inspired concentration) in oxygen. At least 45 min was 
allowed for the short-acting barbiturate to be redistri- 
buted and for stable halothane anesthesia to be achieved. 
As in the previously reported experiments in conscious 
and pentobarbital-anesthetized dogs, the Z-DG was ad- 
ministered as a bolus of either 100 or 300 mg/kg into the 
cephalic (foreleg) vein and flushed in rapidly with saline. 
Blood samples were drawn from the implanted catheter 
at 0 min before and at 5, 15, 30, 45, 50, and 60 min after 
the 2DG injection. In selected experiments, tritiated NE 
( [3H]NE) was infused to determine the rate of NE ap- 
pearance in and clearance from plasma. In these experi- 
ments a bolus of 30 &i of [3H]NE was administered 
intravenously into the cephalic vein followed by an in- 
fusion of 2 &i/min. The infusion was run for 30 min to 
achieve a steady state; then samples were drawn from 
the aortic catheter at -15, -10, -5, and 0 min before 
and at 5, 15, 30, 35, 40, and 45 min after the 2-DG 
injection. 
Assays and data analysis. Blood samples for glucose 
determination were drawn and put into tubes containing 
EDTA. Blood samples for catecholamine measurement 
were drawn and put into tubes containing EGTA and 
glutathione. All blood samples were centrifuged at 4°C 
and frozen at -20°C until assayed. Plasma glucose was 
measured by the glucose-oxidase method using a Tech- 
nicon AutoAnalyzer (Technicon Instruments, San Fran- 
cisco, CA). This method measures 2-DG in plasma with 
35% cross-reactivity relative to glucose. Plasma 2-DG 
concentrations after the injection of 100 and 300 mg/kg 
into dogs have been previously determined (24). To cal- 
culate the plasma glucose response to the sympathetic 
activation induced by 2-DG, the measured values in 
plasma (glucose + 0.35 2-DG) were corrected by subtract- 
ing 35% of the previously measured average value of 2- 
DG in plasma. 
Plasma epinephrine and norepinephrine were mea- 
sured in duplicate using a highly specific and sensitive 
single-isotope radioenzymatic method (9). The intra- and 
interassay coefficients of variation for the plasma cate- 
cholamine assay in this laboratory are 9 and 12%, re- 
spectively. 
The concentration of plasma [3H]NE, required for the 
calculation of specific activity, was determined by liquid 
scintillation counting of radiolabeled NE after extraction 
of the plasma with alumina to remove all NE metabolites. 
Because the [3H]NE infusion rate is constant and known 
and the specific activity of [3H]NE can be measured, the 
endogenous plasma norepinephrine appearance rate can 
be calculated as follows 
NE appearance = [3H]NE infusion rate X 
WE1 
N3HlNEl 
This formula is valid only at steady state, i.e., when the 
[“H]NE infusion rate, the [NE] and the [ [3H]NE] are 
constant. At steady state, the NE clearance rate can be 
calculated by dividing the plasma NE removal rate (equal 
to the appearance rate) by the plasma NE concentration 
(4) 
NE clearance = 
NE removal (appearance) 
WE1 
The change of plasma concentrations of glucose were 
calculated by subtracting the 0-min value from the cor- 
rected 60-min peak value after the injection of 2-DG. 
The changes of plasma concentrations of EPI and the 
changes of plasma NE in the experiments with the 100 
and 300 mg/kg doses of 2DG were calculated by sub- 
tracting the 0-min value from the 30-min value following 
2-DG. The changes of NE appearance rate were calcu- 
lated by subtracting the mean of the -15-, -lo-, -5-, 
and 0-min values from that of the 30-min value after 2- 
DG. The 5- and 15-min values were not used for this 
calculation because [NE] was not constant. 
The data reported in the results are means t SE. 
Statistical comparisons of means within a group were 
made with a paired t test; statistical comparisons of 
means of different groups were made with a two-sampled 
t test. Dunnett’s test was used for multiple comparison 
between more than two groups. 
RESULTS 
Plasma EPI, NE, plasma glucose, and NE kinetic re- 
sponses to 2-DG (100 mg/kg) in halothane-anesthetized 
dogs. Base-line plasma NE averaged 161 t 28 pg/ml in 
halothane-anesthetized dogs, increased to 318 t 63 pg/ 
ml 30 min after 2-DG (A = 157 & 55 pg/ml, P c 0.025), 
and remained elevated for the next 0.5 h (Fig. 1). These 
data are compared in Table 1 to the previously reported 
responses in pentobarbital-anesthetized and conscious 
dogs (23). The NE response to 2-DG was identical to 
that of conscious dogs and significantly larger than that 
of pentobarbital-anesthetized dogs (P < 0.05; Fig. 1). 
Base-line NE appearance in halothane-anesthetized 
dogs was 7 t 1 ng l kg-’ l min-‘. Base-line NE appearance 
was somewhat higher in conscious dogs, 13 t 1 ng . kg-‘. 
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FIG. 1. Change of plasma norepinephrine (NE) in response to 2- 
deoxy-D-glucose (2-DG; 100 mg/kg) in 7 dogs anesthetized with halo- 
thane (0.8%), in 6 dogs anesthetized with pentobarbital (30 mg/kg), 
and in 6 unanesthetized dogs. 
HALOTHANE ON SYMPATHETIC ACTIVATION E669 
TABLE 1. Basal and 2-DG-stimulated NE, EP, 
and glucose levels in halothane-anesthetized, 
conscious, and pentobarbital-anesthetized dogs 
Anesthesia 
Z-D@ (100) 2-DG (300) 
Halo Pento* Cons* Halo Pento* 
(n=7) (n=6) (n=6) (n=6) (n=14) 
Basal [NE], pg/ml 161t28 118t41 138t18 63t22 166t38 
A WEI, P&n1 157t55 3+37j- 143t28 262t33 126*28$ 
Basal EPI, pg/ml 55t21 46t12 128&51 17*8 35t8 
A WII, Pdml 269k86 5+9-f 145t58 707k212 161*34$ 
Basal glucose, mg/dl 96t6 107t3 107t3 103t4 lllt2 
A Glucose, mg/dl 19t6 4+3-f 13*4 30t8 12+3§ 
Values are means & SE. 2-DG, 2-deoxy-D-glucose; NE, norepineph- 
rine; EPI, epinephrine; Halo, halothane (0.8%); Pento, pentobarbital 
(30 mg/kg); Cons, conscious, no anesthesia. * Previously published data 
included for the purpose of comparison with halothane data. 7 P < 0.05 
vs. halothane; $ P < 0.0005 vs. halothane; $ P c .0025 vs. halothane. 
TABLE 2. Plasma NE kinetics in 
halothane-anesthetized, conscious, 
and pentobarbital-anesthetized dogs 
Halo Cons Pento* 
(n=6) (n=8) (n=6) 
Basal NE appearance, ng l kg-l l mine1 
2-DG-stimulated NE appearance, 
ng . kg-l l min-’ 
7tl 13+1t 2+1$ 
17215 24t3 NM 
A at 30 min, ng . kg-’ + min-’ 10t4 llt2 NM 
Basal NE clearance, ml. kg-‘. min-’ 46t3 70+2§ 16+6$j 
Clearance during 2-DG, ml. kg-l. min-’ 52t4 76+5§ NM 
Values are means t SE. NE, norepinephrine; 2-DG, 2-deoxy-D- 
glucose; Halo, halothane anesthesia (0.8%); Pento, pentobarbital an- 
esthesia (30 mg/kg); Cons, conscious, no anesthesia; NM, not measured. 
* Previously published data included for the purpose of comparison. 
t P < 0.025 vs. halothane; $ P < 0.001 vs. halothane; 8 P < 0.0025 vs. 
halothane. 
min-’ (P < 0.025 vs. halothane) but was markedly lower 
in pentobarbital-anesthetized dogs (4), 2 t 1 ng. kg-‘. 
min-l (P < 0.001 vs. halothane). Thirty minutes after 2- 
DG, NE appearance in halothane-anesthetized dogs in- 
creased to 17 t 5 ng l kg-‘. min-1 (A = 10 t 4 ng l kg-‘. 
min-l; P < 0.05). In conscious dogs, 2-DG caused NE 
appearance to increase to 24 t 3 ng l kg-‘. min-’ (A = 11 
t 2 ng l kg-‘. min-‘; P < 0.0005). This increment was 
indentical to that measured in the halothane-anesthe- 
tized dogs (Table 2). NE appearance after 2-DG was not 
measured in pentobarbital-anesthetized dogs. NE clear- 
ance in halothane-anesthetized dogs was 46 t 3 ml l kg-‘. 
min-’ before and 52 t 4 ml kg-‘=min-’ after 2-DG. In 
conscious dogs NE clearance was greater, both before, 70 
-t 2 ml. kg-l l min-‘, and after 2-DG, 76 t 5 ml. kg-’ l 
min-’ (both P < 0.0025 vs. halothane) (Table 2). We 
have previously demonstrated that pentobarbital de- 
creased basal NE clearance to 16 t 6 ml l kg-‘. min-’ (P 
< 0.0025 vs. halothane) (4). NE clearance was not mea- 
sured in pentobarbital-anesthetized dogs receiving 2-DG. 
In dogs anesthetized with halothane, base-line %PI 
averaged 55 t 21 pg/ml. EPI increased to 324 t 102 pg/ 
ml by 30 min after the injection of 100 mg/kg of 2-DG 
(A = 269 t 86 pg/ml, P < 0.025); EPI remained elevated 
during the next 0.5 h. Compared with the previously 
reported data (Table 1) obtained from pentobarbital- 
anesthetized and conscious dogs (23). the EPI response 
to 2-DG in halothane-anesthetized dogs was significantly 
greater than in pentobarbital-anesthetized dogs (P < 
0.05) and not significantly different from that in con- 
scious dogs (Fig. 2). 
Basal plasma glucose in halothane-anesthetized dogs 
was 96 t 6 mg/dl and increased to 115 t 4 mg/dl60 min 
after 2-DG (A = 19 2 6 mg/dl, P < 0.01). These data are 
compared in Table 1 with the previously reported glucose 
responses of conscious and pentobarbital-anesthetized 
dogs. The plasma glucose response to 2-DG in halothane- 
anesthetized dogs was significantly greater than that of 
pentobarbital-anesthetized dogs (P < 0.05; Fig. 3). 
Plasma EPI, NE, and glucose responses to 2-DG (300 
mg/kg) in halothane-anesthetized dogs. In dogs anesthe- 
tized with halothane, plasma NE averaged 63 t 22 pg/ 
ml and increased to 325 t 22 pg/ml 30 min after the 
injection of 300 mg/kg 2-DG. This response (A = 262 t 
33 pg/ml, P < 0.0005) was significantly larger than that 
600 
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FIG. 2. Change of plasma epinephrine (EPI) in response to 2deoxy- 
D-&COSe (2-DG; 100 mg/kg) in 7 dogs anesthetized with halothane 
(0.8%), in 6 dogs anesthetized with pentobarbital (30 mg/kg), and in 6 
unanesthetized dogs. 
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FIG. 3. Change of plasma glucose in response to 2-deoxy-D-glucose 
(2-DG; 100 mg/kg) in 7 dogs anesthetized with halothane (0.8%), in 6 
dogs anesthetized with pentobarbital (30 mg/kg), and in 6 unanesthe- 
tized dogs. 
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in the dogs anesthetized with pentobarbital (P < 0.005; min after Z-DG (A = 30 t 8 mg/dl, P < 0.005). This 
Fig. 4; Table 1). Plasma EPI increased from 17 t 8 pg/ glucose response was significantly larger than that in 
ml to 723 t 206 pg/ml 30 min after injection of 300 mg/ pentobarbital-anesthetized dogs (P < 0.0025; Fig. 6; Ta- 
kg 2-DG into halothane-anesthetized dogs. This response ble 1). In conscious dogs, 2-DG at a dose of 300 mg/kg 
(A = 707 t 212, P < 0.025) was significantly larger than caused convulsions that were quickly terminated by pen- 
the EPI response to 300 mg/kg of 2-DG in pentobarbital- tobarbital injection. Therefore, the comparable data from 
anesthetized dogs (P < 0.0005 (Fig. 5; Table 1. In halo- conscious dogs are not available. 
thane-anesthetized dogs, base-line plasma glucose aver- The mean changes of plasma glucose in the five groups 
aged 103 t 4 mg/dl and increased to 133 -+ 10 mg/dl, 60 of dogs administered 2-DG (100 mg/kg or 300 mg/kg) 
v 2-DG (300mgikg IV) 
correlated with the mean plasma NE and EPI responses 
(r = 0.97, P c 0.005, and r = 0.97, P c 0.005, respectively, 
300- 
"Ee 
n=6 
n = 5). 
PenZZal DISCUSSION 
n=14 
The present studies were designed to determine 
F 200- whether halothane anesthesia suppresses the adrenergic 
\ 
x activation induced by central neuroglucopenia. Finding 
E 
an anesthetic that does not suppress autonomic reflexes 
is of critical importance for studies of reflex neural 
Q loo- control of pancreatic islet function, because many such 
studies require acute surgical access to the superior pan- 
creatic vein. For example, the sampling of pancreatic 
venous blood is necessary for the measurement of pan- 
O- creatic somatostatin output, because neither portal ve- 
I w I 1 nous nor peripheral somatostatin levels are indices of 
0 30 60 pancreatic somatostatin secretion (22). 
Minutes We chose to evaluate halothane anesthesia, because it 
FIG. 4. Change of plasma norepinephrine (NE) in response to 2- 
deoxy-a-glucose (2-DG; 300 mg/kg) in 6 dogs anesthetized with halo- 
has been shown to be less inhibitory than other anes- 
thane (0.8%) and in 14 dogs anesthetized with pentobarbital (30 mg/ 
thetics on certain cardiovascular reflexes (6) and because 
we have demonstrated that low levels of halothane an- kg). 
esthesia (0.8% inspired) allow parasympathetic re- 
sponses to neuroglucopenia that are equivalent to those 
observed in conscious dogs (11). This dose of halothane 
would usually be considered inadequate to produce sur- 
gical anesthesia in dogs (17), but the use of thiamylal 
sodium for the induction anesthesia lowers the minimum 
alveolar concentration value for halothane (8) and en- 
ables an inspired concentration of 0.8% to produce sur- 
gical anesthesia in over 90% of the dogs we have studied. 
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FIG. 5. Change of plasma epinephrine (EPI) in response to 2-deoxy- FIG. 6. Change of plasma glucose in response to 2-deoxy-D-glucose 
D-ghCOse (2-DC; 300 mg/kg) in 6 dogs anesthetized with halothane (2-DC; 300 mg/kg) in 6 dogs anesthetized with halothane (0.8%) and 
(0.8%) and in 14 dogs anesthetized with pentobarbital (30 mg/kg). in 13 dogs anesthetized with pentobarbital (30 mg/kg). 
HALOTHANE ON SYMPATHETIC ACTIVATION E671 
The first set of studies demonstrated that halothane 
anesthesia allows a modest plasma norepinephrine re- 
sponse to 100 mg/kg of 2DG that is equivalent to the 
response observed in conscious dogs (23). To verify that 
the plasma NE response to 2DG in halothane-anesthe- 
tized dogs was due solely to increased NE release, rather 
than to a reduction of plasma NE clearance, we compared 
plasma NE kinetics before and during neuroglucopenia 
in halothane-anesthetized and conscious dogs by the 
isotope-dilution technique. For the measurement and 
calculation of NE kinetics to be valid, it is necessary to 
have reached a steady state. In this study, from 30 to 45 
min after the injection at 2-DG, all of the components 
used to calculate NE appearance and clearance (see 
MATERIALS AND METHODS) had reached a plateau and 
remained constant, thus the required steady state was 
achieved. Although both base-line NE clearance and the 
base-line NE appearance rate were somewhat lower in 
the halothane-anesthetized animals, the increment of 
the NE appearance rate after 2-DG in halothane-anes- 
thetized dogs was identical to that of the conscious dogs. 
Thus, the plasma NE response to 2-DG in halothane- 
anesthetized dogs does reflect an increase of noradrener- 
gic outflow equivalent to that observed in unanesthetized 
animals. Likewise, the EPI response to 100 mg/kg of 2- 
DG was not significantly different from that of normal 
conscious dogs (23). Thus, the adrenomedullary response 
to neuroglucopenic stress, like the systemic noradrener- 
gic response, is not suppressed by this level of halothane. 
Halothane is much less suppressive on autonomic ac- 
tivity than pentobarbital, the anesthetic most commonly 
used in animal experimentation. For example, both the 
norepinephrine and epinephrine responses to 2-DG (100 
mg/kg), which were preserved under halothane, were 
absent under pentobarbital anesthesia (30 mg/kg) (23). 
When a threefold higher dose of 2-DG (300 mg/kg) was 
administered to pentobarbital-anesthetized dogs, modest 
norepinephrine and epinephrine responses did occur, yet 
both NE and EPI responses were significantly larger 
when this same dose of 2-DG was administered to halo- 
thane-anesthetized dogs. Thus, even when the stimulus 
was increased to allow an adrenergic response to neuro- 
glucopenia in pentobarbital-anesthetized animals, this 
anesthesia was still clearly suppressive relative to halo- 
thane. 
Other data also suggest that pentobarbital inhibits 
neurally mediated events. Certain cardiovascular re- 
flexes, with both sympathetic and parasympathetic com- 
ponents, are impaired in pentobarbital-anesthetized an- 
imals (6, 7). More direct measurements demonstrate that 
pentobarbital anesthesia suppresses the plasma cate- 
cholamine responses to hemorrhage (25) and the pan- 
creatic polypeptide response to 2-DG (24). The former is 
a sympathetically mediated reflex response to hypoten- 
sion; the latter is a parasympathetically mediated reflex 
response to central neuroglucopenia (12, 24). 
The mechanisms by which pentobarbital suppresses 
and halothane fails to suppress these autonomic reflexes 
is not known. However, pentobarbital is known to de- 
press central synaptic transmission (lS), and presumably 
halothane has a similar effect related to its ability to 
produce central anesthesia. Thus, perhaps the “higher” 
areas of the central nervous system are equally sup- 
pressed by halothane and pentobarbital, allowing both 
to produce anesthesia, but the “lower” brain areas re- 
sponsible for autonomic reflexes may be less susceptible 
to halothane at the dose used for these studies. Pento- 
barbital has also been demonstrated to block transmis- 
sion across peripheral parasympathetic and sympathetic 
synapses (10, 21) as well as to inhibit axonal conduction 
(14).We have previously demonstrated that halothane 
(0.8%) is less suppressive than pentobarbital (30 mg/kg) 
on peripheral parasympathetic neurotransmission (11). 
Therefore, it is probable that both central and peripheral 
neural communications are less suppressed by halothane 
anesthesia. 
Although the data presented here indicate that halo- 
thane is superior to pentobarbital for the preservation of 
sympathetic responses, other studies of the effect of 
halothane show progressive suppression of cardiovascu- 
lar reflexes in proportion to the concentration of halo- 
thane administered (3). It is therefore important to rec- 
ognize that the difference between halothane and pen- 
tobarbital may be less marked at a higher concentration 
of halothane. 
In these studies, we also measured the plasma glucose 
response to neuroglucopenia as one possible index of the 
metabolic effects of the catecholamines released by 
stress. The glucose response to 100 mg/kg of 2-DG in 
halothane-anesthetized dogs, like the plasma catechola- 
mine response, was equivalent to that of conscious dogs; 
pentobarbital anesthesia abolished both responses (23). 
However, when the stimulus was increased to 300 mg/kg 
of 2-DG, there was a modest plasma glucose response in 
the pentobarbital-anesthetized dogs (23). However, this 
response, like the plasma catecholamine response, was 
significantly smaller than that observed during halo- 
thane anesthesia. Indeed, the plasma glucose response 
was largest when 300 mg/kg of 2-DG was given to halo- 
thane-anesthetized dogs, an experiment that also pro- 
duced the largest catecholamine responses. The close 
correlations between changes of plasma glucose and 
plasma catecholamines suggest that these moderate ad- 
renergic activations are responsible for the plasma glu- 
cose response. Indeed, circulating catecholamines can 
produce these effects because infusions of either NE or 
EPI increase plasma glucose (16, 20). Alternatively, lo- 
cally released NE may be responsible for the plasma 
glucose response, because electrical stimulation of the 
adrenergic nerves to the liver increases plasma glucose 
levels (18). Finally, the effect of more severe neuroglu- 
copenic stress on plasma glucose can be indirect (a), 
because marked sympathetic activation can inhibit in- 
sulin (1, 15) and stimulate glucagon (1, 13), which in 
turn would stimulate hepatic glucose production (5). 
Thus, it is likely that the adrenergic response to 2-DG 
causes the plasma glucose response, however, the dem- 
onstration that halothane allows the plasma glucose 
response to 2-DG does not rule out a possible suppressive 
effect of halothane on other metabolic responses to neu- 
roglucopenic stress. 
In summary, the plasma NE level, the NE appearance, 
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EPI, and glucose responses to 100 mg/kg of Z-DG in 
halothane-anesthetized dogs were indistinguishable from 
those of unanesthetized dogs, whereas in pentobarbital- 
anesthetized dogs, plasma NE, EPI, and glucose re- 
sponses were abolished. A threefold larger dose of Z-DG 
did produce plasma NE, EPI, and glucose responses in 
pentobarbital-anesthetized dogs, but in halothane-anes- 
thetized dogs all of these responses were significantly 
larger. Thus, halothane anesthesia is much less suppres- 
sive than pentobarbital anesthesia and is therefore the 
preferred anesthesia for studying the adrenergic response 
to neuroglucopenic stress and 
consequence of that response. 
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